Circio Holding ASA: Cancellation of Subsequent Offering

Reference is made to the stock exchange announcement made by Circio Holding ASA (the "Company") on 15 September 2026, whereby the Company announced the allocation of 16,865,000 new shares in the Company (the "Offer Shares"), raising gross proceeds of approximately NOK 200 million (the "Private Placement"), and a potential subsequent offering of up to 16,865,000 new shares raising gross proceeds of approximately NOK 200 million at the same subscription price as in the Private Placement (the "Subsequent Offering").

In the period since the announcement of the Private Placement, the Company's shares have traded below the subscription price, which is also currently the case. Trading volumes on days when the shares have traded below the subscription price have been several times the full volume of the potential Subsequent Offering.
 
Consequently, existing shareholders who did not participate in the Private Placement have had the opportunity to acquire shares in the Company at prices below the subscription price and reduce dilutive effects of the Private Placement.
 
Based on the above, the Company has decided to cancel the Subsequent Offering.
 
This information is subject to disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: [phone]
Email: [e-mail]

Lubor Gaal, CFO
Phone: [phone]
Email: [e-mail]

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 60-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.